eng Oriental Scientific Publishing Company Biomedical and Pharmacology Journal 0974-6242 2019-06-25 12 2 603 608 10.13005/bpj/1680 27723 article Anas AlAhmed 1 Hany Ezzat Khalil‎ 1,2 Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 31982, Saudi Arabia. Department of Pharmacognosy, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. The main objective of current study was to investigate the in vitro and in vivo antidiabetic activity of Terfezia claveryi methanol extract. In vitro antidiabetic assays such as inhibition of α-amylase enzyme and non-enzymatic glycosylation of hemoglobin were carried out. The results of α- amylase inhibition assay revealed that the inhibitory activity (IC₅₀) of Terfezia claveryi methanol extract (‎38.7µg/ml) is stronger when compared with positive control (Acarbose IC₅₀ value of ‎45.3‎ µg/ml). The inhibition of glycosylation of hemoglobin of Terfezia claveryi methanol extract showed almost the same IC₅₀ (33.1µg/ml) when compared the positive control, alpha-tocopherol (‎35.4µg/ml‎). In vivo antidiabetic study revealed that Terfezia claveryi methanol extract ‎ possessed good activity at a dose of 200 mg/kg through reducing the fasting plasma glucose level (122.1‎±‎3.0 mg/dl) when compared with positive control (Glibenclamide of ‎79.4±1.4‎ mg/dl) (p < 0.001). The results from this study indicated that Terfezia claveryi methanol extract exhibited considerable in vitro and in vivo antidiabetic activities. These possible activities could be useful to consider Terfezia claveryi ‎ as therapeutic antidiabetic candidate. https://biomedpharmajournal.org/vol12no2/antidiabetic%e2%80%8e-activity-of-terfezia-claveryi-an-in-vitro-and-in-vivo-study/ Antidiabetic α-amylase Hemoglobin Streptozotocin Terfezia